Media stories about Proteostasis Therapeutics (NASDAQ:PTI) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Proteostasis Therapeutics earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.2998238757533 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
A number of analysts have issued reports on PTI shares. ValuEngine upgraded shares of Proteostasis Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Zacks Investment Research lowered shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 18th. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Proteostasis Therapeutics in a research note on Tuesday, December 19th. Royal Bank of Canada started coverage on shares of Proteostasis Therapeutics in a research note on Friday, March 9th. They set an “outperform” rating and a $11.00 price target on the stock. Finally, Leerink Swann boosted their price target on shares of Proteostasis Therapeutics from $6.00 to $8.00 in a research note on Tuesday, December 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. Proteostasis Therapeutics presently has an average rating of “Buy” and a consensus target price of $14.75.
Shares of Proteostasis Therapeutics stock traded down $0.14 during trading hours on Monday, reaching $7.15. 379,820 shares of the company’s stock were exchanged, compared to its average volume of 1,965,031. The stock has a market capitalization of $251.38, a price-to-earnings ratio of -3.02 and a beta of 6.66. Proteostasis Therapeutics has a one year low of $1.41 and a one year high of $13.16.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Proteostasis Therapeutics (PTI) Share Price” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/03/19/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-proteostasis-therapeutics-pti-share-price.html.
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.